Table 6 Univariate and multivariate analysis of predictive factors for CSS in validation cohort (n = 103).

From: FAN score comprising fibrosis-4 index, albumin–bilirubin score and neutrophil–lymphocyte ratio is a prognostic marker of urothelial carcinoma patients treated with pembrolizumab

 

Univariate

Multivariate

HR

95% CI

p

HR

95%CI

p

Lower

Higher

Lower

Higher

Age

 < 73 vs. ≥ 73

1.41

0.84

2.38

0.195

1.32

0.77

2.27

0.308

Sex

Male vs. female

0.83

0.46

1.47

0.516

0.85

0.46

1.56

0.603

Primary site

Upper urinary tract involvement vs. others

0.87

0.52

1.47

0.598

    

Surgical removal of primary site

No vs. yes

1.36

0.68

2.70

0.382

    

Previous chemotherapy regimen

Cisplatin vs. non-cisplatin

0.79

0.47

1.34

0.384

    

Time from last chemotherapy (days)

 ≥ 90 vs. < 90

1.18

0.68

2.04

0.557

    

Hb (g/dl)

 ≥ 10.0 vs. < 10.0

1.93

1.15

3.25

0.013

1.50

0.86

2.63

0.152

ECOG performance status

0 vs. 1

1.86

0.78

4.45

0.163

1.59

0.64

3.91

0.316

0 vs. ≥ 2

5.66

2.25

14.26

 < 0.001

3.87

1.46

10.27

0.007

Metastatic sites

Lymphnode vs. other organs

2.39

1.00

5.68

0.049

1.86

0.77

4.54

0.167

Lymphnode vs. liver metastasis

5.11

2.00

13.03

0.001

3.60

1.37

9.51

0.010

eGFR (ml/min/1.73 m2)

 ≥ 60 vs. 30.0 ≤ , < 60.0

0.69

0.38

1.26

0.227

    

 ≥ 60 vs. < 30

0.74

0.33

1.68

0.741

    

FAN score

Low risk group vs. high risk group

1.41

1.08

1.84

0.011

1.48

1.19

1.85

0.001

  1. Hb: hemoglobin, ECOG: Eastern Cooperative Oncology Group, eGFR: estimated glomerular filtration rate, FAN: Fib-4 index, ALBI score and NLR, HR: hazard ratio, CI: confidence interval.
Back to article page